These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25039102)

  • 1. [Future perspectives of hepatitis C therapeutics].
    Sakamoto N
    Hokkaido Igaku Zasshi; 2014 May; 89(1):13-15. PubMed ID: 25039102
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluating the efficacy of interferon therapy on hepatitis C patients].
    Shiraha H; Iwasaki Y; Shiratori Y
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):489-92. PubMed ID: 15359847
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations.
    Khalid O; Bacon BR
    Clin Liver Dis; 2011 Aug; 15(3):573-83. PubMed ID: 21867937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Virus factors determining the outcome of IFN treatment for chronic hepatitis C].
    Kanazawa N; Nakagawa M; Watanabe H; Sakamoto N; Enomoto N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):474-80. PubMed ID: 15359844
    [No Abstract]   [Full Text] [Related]  

  • 5. HCV NS5A inhibitors in development.
    Suk-Fong Lok A
    Clin Liver Dis; 2013 Feb; 17(1):111-21. PubMed ID: 23177287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The end of the beginning for hepatitis C treatment.
    Dieterich D
    Hepatology; 2012 Mar; 55(3):664-5. PubMed ID: 22174100
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon-Free Regimen for Hepatitis C: Insight and Management.
    Masoud MS; Ashfaq UA; Khalid H
    Crit Rev Eukaryot Gene Expr; 2018; 28(4):373-384. PubMed ID: 30311586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection.
    Alestig E; Arnholm B; Eilard A; Lagging M; Nilsson S; Norkrans G; Wahlberg T; Wejstål R; Westin J; Lindh M
    BMC Infect Dis; 2011 May; 11():124. PubMed ID: 21569441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [IL-28B polymorphism and hepatitis C: impact on viral clearance--prolonged, spontaneous and after treatment with antiviral drugs].
    Halfon P; Cacoub P
    Rev Med Interne; 2011 May; 32(5):271-4. PubMed ID: 21126807
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenomics. Gene variants affect hepatitis C treatment, but link is elusive.
    Wapner J
    Science; 2010 Oct; 330(6004):579. PubMed ID: 21030622
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hepatitis C virus infection--after 20 years].
    Pár A
    Orv Hetil; 2010 Mar; 151(12):485-93. PubMed ID: 20231132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of hepatitis C.
    Sievert W; Batey RG
    Med J Aust; 1999 Mar; 170(5):200-2. PubMed ID: 10092915
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 14. New therapeutic strategies for hepatitis C.
    Di Bisceglie AM; McHutchison J; Rice CM
    Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclophilin inhibitors for hepatitis C therapy.
    Membreno FE; Espinales JC; Lawitz EJ
    Clin Liver Dis; 2013 Feb; 17(1):129-39. PubMed ID: 23177289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
    Kneteman NM; Howe AY; Gao T; Lewis J; Pevear D; Lund G; Douglas D; Mercer DF; Tyrrell DL; Immermann F; Chaudhary I; Speth J; Villano SA; O'Connell J; Collett M
    Hepatology; 2009 Mar; 49(3):745-52. PubMed ID: 19072827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
    Lee C
    Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection fighters. Hepatitis C--is a cure possible?
    TreatmentUpdate; 2005; 17(1):8-9. PubMed ID: 17225319
    [No Abstract]   [Full Text] [Related]  

  • 19. [Treatment for hepatitis C under hemodialysis].
    Izumi N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():294-9. PubMed ID: 26845948
    [No Abstract]   [Full Text] [Related]  

  • 20. IL-28B polymorphism and response to anti-hepatitis C therapy.
    Abbas Z
    J Pak Med Assoc; 2011 Jul; 61(7):621-2. PubMed ID: 22204230
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.